Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albiflorin is a natural monoterpene glycoside primarily isolated from the roots of *Paeonia lactiflora* (Radix Paeoniae Alba). It is a structural isomer of paeoniflorin and is recognized for its diverse pharmacological activities, including anti-inflammatory, analgesic, and neuroprotective properties. In neuropsychiatry, albiflorin has been investigated for its antidepressant-like effects, which are thought to involve the modulation of monoamine neurotransmitters such as serotonin and norepinephrine, as well as the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, research indicates its potential as an antineoplastic agent; specifically, it has been shown to inhibit the Wnt/β-catenin signaling pathway, thereby suppressing tumor cell proliferation and enhancing the antitumor effects of other agents like propofol in hepatocellular carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albiflorin.